Form 4: Director Bryan Giraudo Executes PTGX Stock Options

Director Bryan Giraudo exercised options for 36,000 shares of Protagonist Therapeutics and subsequently sold them.

Summary

• Director Bryan Giraudo exercised stock options for 36,000 shares of Protagonist Therapeutics (PTGX) on May 7, 2026.
• The options were exercised at strike prices of $6.45 and $6.98 per share.
• Following the exercise, the director sold a total of 54,130 shares across May 7 and May 8, 2026, at prices ranging from $98.69 to $104.67.
• The transactions resulted in a reduction of the director's direct and indirect beneficial ownership.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event; while insider selling can be perceived negatively, this transaction appears to be a routine exercise of vested options.

Positives

• The director demonstrated confidence in the company's long-term value by holding the options until near their expiration dates.
• The exercise of options provided liquidity to the director at a significant premium to the original strike prices.

Negatives

• The director liquidated a significant portion of their holdings, which may be perceived as a lack of long-term conviction by some market participants.

Risks

• Insider selling can sometimes signal that management believes the stock price has reached a near-term peak.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling is common in the biotechnology sector following significant share price appreciation, often related to clinical trial milestones or regulatory progress.

Comparison to Industry Standards

• The exercise and sale of vested options is a standard practice for corporate directors and executives in the biotech industry.
• The volume of shares sold is consistent with typical portfolio rebalancing for directors of mid-cap pharmaceutical companies.

Stakeholder Impact

• Shareholders may monitor insider activity for signals regarding the company's valuation.
• No direct impact on employees, customers, or creditors.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

Protagonist Therapeutics, PTGX, Insider Trading, Form 4, Stock Options, Biotech